Yann Dean

Title: Yann Dean: Innovator in Antibody Development

Introduction

Yann Dean is a prominent inventor based in Bossey, France, known for his significant contributions to the field of antibody development. With a total of six patents to his name, he has made remarkable strides in cancer treatment and immunology.

Latest Patents

One of his latest patents is the Anti-netrin-1 antibody. This application discloses a method of treating cancer by utilizing a linear or substantially linear epitope on netrin-1, which corresponds to the specific binding region of netrin-1 to its receptor, particularly the UNC5 class, especially UNC5B and UNC5A. This innovation allows for the production of antibodies that bind to netrin-1, interfering with its interaction with receptors, thereby inducing apoptosis or cell death in tumor cells that express or overexpress netrin-1. Another significant patent is related to Anti-CD3 antibodies, which are directed to the antigen CD3. This invention provides fully human monoclonal antibodies directed to CD3, along with nucleotide sequences encoding these immunoglobulin molecules.

Career Highlights

Yann Dean has worked with notable companies in the biotechnology sector, including Novimmune SA and Netris Pharma. His work has focused on developing innovative therapeutic solutions that leverage the power of monoclonal antibodies.

Collaborations

Throughout his career, Yann has collaborated with esteemed colleagues such as Bernard Francois Mach and Marie Kosco-Vilbois, contributing to advancements in the field of immunotherapy.

Conclusion

Yann Dean's innovative work in antibody development has the potential to significantly impact cancer treatment and immunology. His contributions continue to pave the way for new therapeutic approaches in medicine.